[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 4 days · First seen · Last updated

EssilorLuxottica optical technology developments

Overview

EssilorLuxottica is managing divergent developments regarding its optical technologies. The company has received FDA De-Novo authorization in the United States for Stellest lenses, which are designed to slow myopia progression in children. Clinical trials published in JAMA Ophthalmology indicate that these lenses, which utilize highly aspherical lenslets, can slow myopia progression by an average of 71 percent and reduce axial elongation by 53 percent compared to conventional lenses.

Simultaneously, the company is facing social and regulatory scrutiny over its AI-integrated smart glasses, specifically the Ray-Ban Meta collaboration. Despite significant sales in 2025, analysts have warned of a potential market downturn driven by privacy and surveillance concerns. Critics have expressed fears regarding the difficulty of detecting these devices, with some labeling them ‘pervert glasses’ due to the potential for filming individuals without consent.

Entities

EssilorLuxottica · FDA · Meta Platforms · Bernstein · JAMA Ophthalmology

Timeline

  1. 13 days ago

    [HEALTH] 2 sources
    Essilor Stellest lenses slow myopia progression by 71% in US trial

    A US clinical trial published in JAMA Ophthalmology shows Essilor Stellest lenses slow myopia progression in children by 71% over 24 months.

  2. 16 days ago

    [BUSINESS] 2 sources
    EssilorLuxottica faces privacy backlash and FDA approval

    EssilorLuxottica faces a dual reality: receiving FDA approval for myopia-slowing Stellest lenses while navigating a privacy backlash against its Meta-partnered smart glasses.

Sources

brevenews.com · insightnews.com.au · it-boltwise.de · nemosnewsnetwork.com